Published in Am J Respir Cell Mol Biol on December 18, 2008
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun (2009) 1.58
The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res (2014) 1.25
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One (2011) 1.11
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release (2012) 1.04
AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One (2013) 1.03
Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther (2012) 0.99
An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models. Sci Rep (2014) 0.98
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis (2011) 0.97
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One (2012) 0.95
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Res (2015) 0.95
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett (2013) 0.93
The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer (2014) 0.93
Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90
Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. ACS Chem Biol (2013) 0.88
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Cancer Res (2014) 0.87
Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid model. PLoS One (2012) 0.85
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal (2012) 0.83
Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis. BMC Cancer (2014) 0.80
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Mol Cancer Ther (2015) 0.79
Pretreatment with Lycopene Attenuates Oxidative Stress-Induced Apoptosis in Human Mesenchymal Stem Cells. Biomol Ther (Seoul) (2015) 0.79
Rounding up apoptosis resistance targets in lung cancer. Am J Respir Cell Mol Biol (2009) 0.79
Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol (2014) 0.78
Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett (2015) 0.77
Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models. PLoS One (2015) 0.76
Pretreatment with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-D-pyranoside attenuates cerebral ischemia/reperfusion-induced injury in vitro and in vivo. PLoS One (2014) 0.76
Edaravone mitigates hexavalent chromium-induced oxidative stress and depletion of antioxidant enzymes while estrogen restores antioxidant enzymes in the rat ovary in F1 offspring. Biol Reprod (2014) 0.76
A Novel 3-D Cell Culture System for In Vitro Evaluation of Anticancer Drugs under Anchorage-Independent Conditions. Cancer Sci (2016) 0.75
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA J (2012) 0.75
Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population. Cancer Med (2016) 0.75
MORIN MITIGATES OXIDATIVE STRESS, APOPTOSIS AND INFLAMMATION IN CEREBRAL ISCHEMIC RATS. Afr J Tradit Complement Altern Med (2017) 0.75
Sesamol attenuates oxidative stress, apoptosis and inflammation in focal cerebral ischemia/reperfusion injury. Exp Ther Med (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 11.09
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Intrinsic tumour suppression. Nature (2004) 8.73
The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol (2007) 7.38
Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer (2008) 5.35
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res (2008) 3.58
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene (2004) 2.36
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med (2008) 2.22
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res (2002) 2.05
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2006) 1.84
Dynamics of the self-assembly of complex cellular aggregates on micromolded nonadhesive hydrogels. Tissue Eng (2007) 1.69
A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem (2001) 1.56
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene (2007) 1.47
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem (2008) 1.45
c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res (2007) 1.43
Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev (1994) 1.42
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene (2003) 1.39
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem (2005) 1.38
Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A (1994) 1.36
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34
Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med (2006) 1.21
Apoptosis and lung cancer: a review. J Cell Biochem (2003) 1.21
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol (2005) 1.19
Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med (2002) 1.18
Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem (2004) 1.11
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther (2007) 1.11
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother (2005) 1.09
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther (2004) 1.06
alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem (2005) 1.04
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol (2008) 1.01
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab (2007) 1.01
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer (2005) 0.98
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol (2006) 0.97
Preclinical data with bortezomib in lung cancer. Clin Lung Cancer (2005) 0.91
FLIP protects against hypoxia/reoxygenation-induced endothelial cell apoptosis by inhibiting Bax activation. Mol Cell Biol (2005) 0.91
Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res (2001) 0.86
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer (2007) 0.85
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biol Ther (2007) 0.85
Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. Oncogene (2006) 0.84
Development of luciferase reporter-based cell assays. Assay Drug Dev Technol (2006) 0.83
Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clin Cancer Res (2007) 0.78
The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol (2002) 4.60
Small-cell lung cancer. Lancet (2011) 3.61
MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74
Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest (2007) 1.73
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem (2008) 1.45
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res (2009) 1.34
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res (2009) 1.28
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res (2007) 1.27
New advances in the second-line treatment of small cell lung cancer. Oncologist (2009) 1.25
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res (2007) 1.19
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue. Am J Pathol (2003) 1.16
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One (2011) 1.11
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res (2005) 1.11
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol (2005) 1.04
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res (2008) 1.04
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther (2008) 1.04
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol (2008) 1.01
H(2)O(2) inhibits alveolar epithelial wound repair in vitro by induction of apoptosis. Am J Physiol Lung Cell Mol Physiol (2004) 1.01
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer (2011) 0.98
c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem (2003) 0.98
Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol (2011) 0.98
Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis. Lung (2007) 0.98
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proc Natl Acad Sci U S A (2014) 0.98
Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One (2011) 0.98
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol (2011) 0.97
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther (2007) 0.96
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One (2012) 0.95
RanGTPase: a candidate for Myc-mediated cancer progression. J Natl Cancer Inst (2013) 0.93
Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy. J Cancer (2011) 0.92
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res (2011) 0.92
Mesothelial cell proliferation and apoptosis. Respirology (2004) 0.92
Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis (2011) 0.91
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol (2012) 0.88
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax (2007) 0.88
Prognostic factors in mesothelioma. Lung Cancer (2005) 0.87
A TMA de-arraying method for high throughput biomarker discovery in tissue research. PLoS One (2011) 0.86
Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res (2007) 0.86
Ultra-fast processing of gigapixel Tissue MicroArray images using high performance computing. Anal Cell Pathol (Amst) (2010) 0.85
Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression. Cancer Sci (2012) 0.84
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. Leuk Res (2002) 0.83
Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. BMC Cancer (2010) 0.83
In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. Int J Cancer (2002) 0.82
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials (2011) 0.81
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer (2012) 0.80
The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget (2013) 0.80
Outcome of hematopoietic stem cell recipients who were mechanically ventilated and admitted to intensive care units. J Formos Med Assoc (2007) 0.79
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS One (2013) 0.79
Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Cancer Res (2011) 0.78
In arrayed ranks: array technology in the study of mesothelioma. J Thorac Oncol (2009) 0.78
Dynamical systems analysis of mitochondrial BAK activation kinetics predicts resistance to BH3 domains. PLoS One (2008) 0.78
Workshop on lung disease and the environment: where do we go from here? Am J Respir Crit Care Med (2003) 0.77
Implications for powering biomarker discovery studies. J Mol Diagn (2012) 0.76
Ligation of CM1 enhances apoptosis of lung cancer cells through different mechanisms in conformity with EGFR mutation. Int J Oncol (2012) 0.75
Ultra-fast processing of gigapixel Tissue MicroArray images using high performance computing. Cell Oncol (Dordr) (2011) 0.75
Malignant mesothelioma as both a challenge and an opportunity. Oncogene (2004) 0.75
Machine vision based stochastic analysis of cancer cell mitochondrial dysfunction induced by a BH3 domain. Apoptosis (2008) 0.75